Biotech Firms, Billions At Risk, Lobby States To Limit Generics by Andrew Pollack. The New York Times. January 28, 2013.
The 2010 Affordable Care Act called for competition for biotechnological drugs. However actions in the states legislatures may have significant impact on the degree of competition and the amount of savings to be realized under ACA from prescribing biosimilars.
How biological drugs are made is outlined here.
No comments:
Post a Comment